Results

1–10 of 248 results for Macular Edema

Senolytic Candidate UBX1325 for Diabetic Macular Edema: The BEHOLD Phase 2 and ASPIRE Phase 2b Trials
Dante Joseph Pieramici, MD
Annual Meeting Talks
2025
Efficacy and Safety Outcomes Over 12 Weeks With OCS-01 Eye Drops in DME From DIAMOND-Stage 1 Trial:Focus on Subgroup by Prior Treatment Status
Baruch D. Kuppermann, MD, PhD
Annual Meeting Talks
2025
Suprachoroidal Avoralstat, a Plasma Kallikrein Inhibitor, Stops Vascular Leakage in a Well-Established RabbitModel
Dilsher S. Dhoot, MD
Annual Meeting Talks
2025
A Phase I Study to Evaluate the Tie2 Agonist RO7446603, Alone or in Combination With Aflibercept orFaricimab, in Diabetic Macular Edema
Jeremiah Brown, MD, MS, FASRS
Annual Meeting Talks
2025
Impact of PDS in Study Eyes vs Anti-VEGF Injections in Fellow Eyes in Pagoda Trial Patients With BilateralDiabetic Macular Edema (DME)
Jordan M. Graff, MD, FACS
Annual Meeting Talks
2025
Interim Results From the SPECTRA Phase 2a Clinical Trial Evaluating Intravitreal 4D-150 in Adults WithDiabetic Macular Edema
David RP Almeida, MD, MBA, PhD, DABO, FRCSC, FASRS
Annual Meeting Talks
2025
Aflibercept 8 mg in Diabetic Macular Edema: 156-Week Results From the PHOTON Extension Study
Eric W Schneider, MD
Annual Meeting Talks
2025
Early Insights From Real-World Use of Aflibercept 8 mg Among Eyes With Diabetic Macular Edema SwitchingFrom Other Anti-VEGF Agents
Michael Javaheri, MD
Annual Meeting Talks
2025
VERONA: End-of-Study Results From a Phase 2 Trial of EYP-1901 (Vorolanib Intravitreal Insert) vs Afliberceptfor Diabetic Macular Edema
Yasha S Modi, MD
Annual Meeting Talks
2025
Comparability of Diabetic Retinopathy Severity Evaluation on Gold Standard vs Ultra-Widefield Images in YOSEMITE/RHINE Phase 3 Studies
Barbara A. Blodi, MD
Annual Meeting Talks
2025